Where does Minerva Biotechnologies Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Minerva Biotechnologies Corporation ranks #12,120 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Minerva Biotechnologies Corporation hold?

Minerva Biotechnologies Corporation holds 25 US utility patents granted between 2017 and 2025, spanning 13 technology areas.

What is Minerva Biotechnologies Corporation's Innovation Score?

Minerva Biotechnologies Corporation has an Innovation Score of 55.1 out of 100 (top 7% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Minerva Biotechnologies Corporation focus on?

Minerva Biotechnologies Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 21 patents, ranking #933 of 6,058 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Minerva Biotechnologies Corporation's patent grant rate increasing or decreasing?

Minerva Biotechnologies Corporation's recent grant velocity is +325% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Minerva Biotechnologies Corporation's patents?

Minerva Biotechnologies Corporation's patents average 18.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Minerva Biotechnologies Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Minerva Biotechnologies Corporation

USPTO PatentsView assignee record - 25 granted patents across 13 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Minerva ranks #12,120 of 49,997 tracked US assignees by granted-patent volume, with 25 patents across 13 technology areas.

#12,120
of 49,997 US assignees by volume: Top 7%
by Innovation Score (55.1/100): 18.5
avg claims per patent: +325%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12120 · US Corporation #12,120 · 25 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 25 grants
UPPER-Q #12,120/49,997
PHOTO-FINISH Medinstill Development
CPC-FOCUS A61P · 13 areas
INNOV-PAR 55.1/100
CLAIMS-RICH 18.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +325% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Medinstill Development LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Minerva’s 55.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.3 pts (21%) Velocity 20.0 pts (36%) Breadth 12.7 pts (23%) Claim depth 11.1 pts (20%)

Qualcomm Incorporated · highest

85
Brandeis University · near

55
Doosan Heavy… · near

55
Minerva Biotechnolog… · this assignee

55
Monosol · near

55
TTP · near

55
3D Lighting… · lowest

7

What this shows Minerva's Innovation Score is 55.1/100 (top 7% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Minerva?

Each dot is one of Minerva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Minerva’s own 18.5 claims/patent is ABOVE the 14.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Minerva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Minerva's grants concentrate

Minerva Biotechnologies Corporation is a focused PatentsView assignee: 13 CPC subclasses with 84% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (10 grants) versus a trough of 1 in 2017. By volume, Minerva sits between Medinstill Development LLC and MU Ionic Solutions Corporation.

Minerva's three-year grant acceleration

Minerva Biotechnologies Corporation shows 14 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Medinstill Develo…

25
Medisca Pharmaceu…

25
Metabolon

25
Mighty Fire Break…

25
Ming Shin Tools

25
Minnetronix

25
Mitsubishi Alumin…

25
MU Ionic Solutions

25
Minerva Biotechno… ◀

25

What this shows Minerva holds 25 patents at rank #12,112, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Minerva

By rank, the assignees closest to #12,112 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Minerva's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Minerva, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Minerva ranks #933 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (55 here).

TTP Plc 55 Monosol, LLC 55 Brandeis University 55 Doosan Heavy Industries & Construction Co., Ltd. 55

Minerva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

55 Top 7% higher than 93% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Minerva Biotechnologies Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	4.0%
2018	2	8.0%
2019	1	4.0%
2020	2	8.0%
2021	1	4.0%
2023	4	16.0%
2024	10	40.0%
2025partial year	4	16.0%

Which technologies does Minerva Biotechnologies Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 21

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 20

C07K - Peptides 17

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

C07D - Heterocyclic Compounds 1

G02B - Optical Elements, Systems OR Apparatus 1

G11B - Information Storage Based ON Relative Movement Between Record Carrier AND Transducer 1

G02F - Optical Devices OR Arrangements FOR THE Control OF Light BY Modification OF THE Optical Properties OF THE Media OF THE Elements Involved THEREIN; Non-linear OPTICS; Frequency-changing OF LIGHT; Optical Logic ELEMENTS; Optical ANALOGUE/DIGITAL Converters 1

C12Y - Enzymes 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Minerva Biotechnologies Corporation's patent record in context - here's where to go next.

Minerva Biotechnologies Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #12,120 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Minerva Biotechnologies Corporation against Medinstill Development LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 55.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.